Bristol Childhood Leukaemia Research Consortium
The long term research vision for the Consortium is to achieve real time identification of patients with leukaemia with evolving relapse, the characterisation of the genetic and pharmacological basis of their disease resistance and the ability to offer innovative interventional therapy (pharmacological, genetic or cellular).
Key to this achievement will be the need to build on the existing expertise available within the University of Bristol, National Blood Transfusion Service and Bristol Royal Hospital for Children and the development of existing and future national and international collaborations.
The Bristol Childhood Leukaemia Research Consortium incorporates 3 major research programs: Minimal Residual Disease, Epigenetic control of gene expression and Experimental Therapeutics. The purpose of the website is to publicise the research activities of the groups.